Mirae Asset Global Investments Co. Ltd. Sells 44,290 Shares of BioNTech SE (NASDAQ:BNTX)

Mirae Asset Global Investments Co. Ltd. reduced its position in BioNTech SE (NASDAQ:BNTX) by 54.6% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,813 shares of the company’s stock after selling 44,290 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in BioNTech were worth $3,885,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of BNTX. Eagle Bay Advisors LLC purchased a new position in BioNTech during the second quarter worth about $33,000. State of Wyoming bought a new stake in shares of BioNTech during the 2nd quarter valued at about $26,000. Covestor Ltd purchased a new position in shares of BioNTech during the third quarter worth about $32,000. Resurgent Financial Advisors LLC bought a new position in shares of BioNTech in the fourth quarter worth approximately $47,000. Finally, UMB Bank n.a. purchased a new stake in BioNTech in the fourth quarter valued at approximately $50,000. 15.52% of the stock is currently owned by institutional investors.

BioNTech Stock Down 1.8 %

BNTX opened at $86.34 on Wednesday. BioNTech SE has a 12 month low of $85.21 and a 12 month high of $129.10. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The business’s 50-day moving average price is $91.67 and its 200-day moving average price is $97.64. The company has a market cap of $20.53 billion, a P/E ratio of 20.96 and a beta of 0.23.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a return on equity of 4.60% and a net margin of 24.26%. On average, equities analysts expect that BioNTech SE will post -1.67 EPS for the current year.

Analyst Ratings Changes

BNTX has been the subject of a number of research reports. HC Wainwright cut their price target on shares of BioNTech from $133.00 to $107.00 and set a “buy” rating for the company in a research note on Tuesday, January 23rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $171.00 target price on shares of BioNTech in a research report on Thursday, March 21st. Oppenheimer began coverage on BioNTech in a research report on Friday, January 5th. They set a “market perform” rating on the stock. JPMorgan Chase & Co. cut their price objective on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a report on Friday, March 22nd. Finally, BMO Capital Markets reduced their price objective on BioNTech from $127.00 to $123.00 and set an “outperform” rating on the stock in a research report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $120.40.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.